P21 vs NA-Selank Amidate
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: P021, Ac-DGGLAG-NH2
P21 (also written P021) is a small synthetic peptide reverse-engineered from the most active region of ciliary neurotrophic factor (CNTF), with an adamantane group bolted on to help it survive in the body and reach the brain. It is studied as a neurogenic and neurotrophic compound for Alzheimer's disease and other memory disorders, with the appeal of getting CNTF-like benefits in a small, orally available molecule. The honest status: it looks genuinely promising in mouse models, but the entire evidence base comes from a single research group and there are no human trials.
Also: N-Acetyl Selank Amidate, NA-Selank
NA-Selank Amidate is a chemically stabilized version of Selank, a Russian anxiolytic peptide derived from the immune fragment tuftsin. The acetyl group on one end and the amide on the other are there to slow enzymatic breakdown, which is a real and sensible modification. What has not been established is whether that translates into a meaningfully better result than plain Selank in humans.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
- NA-Selank Amidate has stronger research evidence (Human Trials) compared to P21 (Animal Studies).
Detailed Comparison
| Attribute | P21 | NA-Selank Amidate |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | P21 is a peptidergic CNTF mimetic, meaning it was designed to copy the active part of the natural neurotrophic factor CNTF without the downsides of the full protein. In rodent studies it boosts neurogenesis in the dentate gyrus of the hippocampus and raises brain-derived neurotrophic factor (BDNF), apparently by inhibiting leukemia inhibitory factor (LIF) signaling. Higher BDNF in turn dampens the activity of GSK-3 beta, a major enzyme that drives abnormal tau phosphorylation, which is the proposed link to reduced Alzheimer-type pathology. These are real findings in animals, but the framing of P21 as a clean single-pathway BDNF booster is a simplification of a still-incomplete picture. | Selank is a synthetic analog of tuftsin, a naturally occurring immunomodulatory peptide fragment. Its reported mechanism has two strands. The first is modulation of GABAergic signalling, which is the basis of its anxiolytic reputation, achieved without the sedation, tolerance or dependence associated with benzodiazepines. The second is an effect on the balance of monoamines and on BDNF expression, which is where the cognitive and mood claims come from. It also retains some of tuftsin's immunomodulatory activity, including effects on interleukin expression. The N-acetylation and C-terminal amidation in this version block the exopeptidases that would otherwise clip the peptide quickly, extending how long it survives after administration. That is a pharmacokinetic change, not a new mechanism. |
| Common Dosing | Limited community data available See research protocols | 250-500 mcg daily (intranasal) Once or twice daily |
| Administration | Oral (nasal in some studies) | Intranasal is the standard route. Subcutaneous is reported but less common. |
| Typical Duration | Ongoing supplementation in studies | Community protocols commonly report 2-4 weeks, though Selank's clinical use does not indicate a dependence risk requiring cycling |
| Best Time to Take | Morning | Morning or split across the day |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The research record on P21 is preclinical and concentrated in the work of Iqbal, Kazim and colleagues. In a 3xTg triple-transgenic mouse model of Alzheimer's disease, chronic oral P021 reduced tau hyperphosphorylation, increased BDNF, enhanced neurogenesis and improved memory performance (J Alzheimers Dis, 2014). Later work in the same line showed P021 prevented dendritic and synaptic deficits and cognitive impairment in animal models, and related studies extended it to Down syndrome and CDKL5 deficiency mouse models. The consistent thread is that across multiple rodent disease models the compound improves synaptic and cognitive measures with a favorable tolerability profile in those animals. The major limitation is that there are no published human clinical trials, no human safety data, and the evidence comes largely from one collaborating group, so independent replication and any translation to people remain open questions. | Selank itself has a real research base, almost all of it Russian, including clinical work in generalised anxiety disorder where it performed comparably to benzodiazepines without the sedation and withdrawal profile, plus animal work supporting the BDNF and monoamine effects. That literature is genuine but it is largely published in Russian journals, has not been replicated in large Western trials, and has not been through FDA or EMA assessment. The amidate variant specifically has essentially no independent published pharmacology. The stability argument is chemically sound and is the same modification used across many research peptides, but nobody has published a human comparison showing it outperforms standard Selank at equivalent doses. Treat the parent compound's evidence as real but geographically narrow, and the variant's advantage as plausible rather than demonstrated. |
Frequently Asked Questions: P21 vs NA-Selank Amidate
What is the difference between P21 and NA-Selank Amidate?
P21 is a cognitive peptide that p21 (also written p021) is a small synthetic peptide reverse-engineered from the most active region of ciliary neurotrophic factor (cntf), with an adamantane group bolted on to help it survive in the body and reach the brain. it is studied as a neurogenic and neurotrophic compound for alzheimer's disease and other memory disorders, with the appeal of getting cntf-like benefits in a small, orally available molecule. the honest status: it looks genuinely promising in mouse models, but the entire evidence base comes from a single research group and there are no human trials. NA-Selank Amidate is a cognitive peptide that na-selank amidate is a chemically stabilized version of selank, a russian anxiolytic peptide derived from the immune fragment tuftsin. the acetyl group on one end and the amide on the other are there to slow enzymatic breakdown, which is a real and sensible modification. what has not been established is whether that translates into a meaningfully better result than plain selank in humans. The main differences lie in their mechanisms of action and clinical applications.
Which is better, P21 or NA-Selank Amidate?
Neither is universally "better" - the choice depends on your specific goals. P21 is typically used for cognitive purposes, while NA-Selank Amidate is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can P21 and NA-Selank Amidate be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using P21 and NA-Selank Amidate together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.